Guard Therapeutics International AB (publ) (GUARD.ST)

Guard Therapeutics International AB (publ) (GUARD.ST) — VMCI valuation read

Guard Therapeutics International AB (publ) (GUARD.ST) carries a VMCI composite of 40/100, 10 points below the Healthcare sector median of 50. Among mid-cap names, that gap places GUARD.ST in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The GUARD.ST insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads GUARD.ST trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 3.5x is the binding constraint on the bear case, the line to track on Guard Therapeutics International AB (publ)'s next 10-Q.

GUARD.ST held flat 0.0% over the trailing 7 days, with a -17.8% read on a 30-day basis.